New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:20 EDTNUVANuVasive called a name to own at William Blair
Following the company's investor meeting, William Blair calls NuVasive a name to own at current share levels. The firm expects the company's performance to improve going forward, starting in Q4.
News For NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
08:48 EDTNUVAInvestors should look at several medtech stocks, says BMO Capital
BMO Capital believes that macro issues have caused declines in medtech stocks. However, the firm thinks that the sector dealt with pricing issues years ago, while patient volumes are rising and larger cap names in the sector have "relatively stable revenue streams." BMO recommends that investors look at stocks with "reasonable multiples," such as Medtronic (MDT), those with new product pipelines such as Boston Scientific (BSX) and Edwards Lifesciences (EW), and those with small-cap product cycles, including Nevro (NVRO), NuVasive (NUVA), and Endologix (ELGX).
06:53 EDTNUVALDR Holding not a proxy for broader spine market, says Northland
After the company preannounced Q3 revenue that came in slightly below the consensus, Northland analyst Mark Landy says LDR Holding (LDRH) is a not a proxy for the broader spine market. The vast majority of LDR's sales are from niche products, Landy tells investors in a research note. As such, he believes last night's news should not be extrapolated to NuVasive (NUVA) and K2M Group (KTWO). He thinks the consensus estimates for LDR's MOBI-C growth in 2015 may have been a "touch optimistic" given a slower than expected broadening of reimbursement for two-level use. He keeps an Outperform rating on LDR Holding with a $38 price target.
October 7, 2015
11:32 EDTNUVALeerink medical supplies/devices analyst holds analyst/industry conference call
Subscribe for More Information
October 6, 2015
10:00 EDTNUVAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Communications Sales & Leasing (CSAL) upgraded to Overweight at Morgan Stanley... FedEx (FDX) upgraded on upcoming positive catalysts at Stifel... Mediaset (MDIUY) upgraded to Buy from Hold at HSBC... Melco Crown (MPEL) upgraded to Hold from Sell at Deutsche Bank... NuVasive (NUVA) upgraded to Buy at Canaccord... SJM Holdings (SJMHY) upgraded to Hold from Sell at Deutsche Bank... Select Medical (SEM) upgraded on expected EBITDA jump at Wells Fargo... Smart & Final Stores (SFS) upgraded to Overweight from Equal Weight at Barclays... Springleaf (LEAF) upgraded to Outperform from Market Perform at Keefe Bruyette... Tanger Factory (SKT) upgraded to Neutral from Underperform at BofA/Merrill.
07:55 EDTNUVANuVasive upgraded to Buy at Canaccord
As reported previously, Canaccord upgraded NuVasive to Buy from Hold as they believe a current and projected strong U.S. macro environment for the broad spine market offsets tough comps and will continue to provide a solid tailwind. The firm also sees continued margin expansion and integration of its iGA platform strategy. Canaccord raised its price target to $58 from $52 on NuVasive shares.
06:08 EDTNUVANuVasive upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
06:07 EDTNUVANuVasive upgraded to Buy from Hold at Canaccord

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use